Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 2
2006 1
2008 4
2009 5
2010 2
2011 3
2012 8
2013 8
2014 4
2015 6
2016 5
2017 6
2018 10
2019 10
2020 16
2021 1
Text availability
Article attribute
Article type
Publication date

Search Results

81 results
Results by year
Filters applied: . Clear all
Page 1
Economic Evaluation of Dupilumab for Moderate-to-Severe Atopic Dermatitis: A Cost-Utility Analysis.
Zimmermann M, Rind D, Chapman R, Kumar V, Kahn S, Carlson J. Zimmermann M, et al. Among authors: carlson j. J Drugs Dermatol. 2018 Jul 1;17(7):750-756. J Drugs Dermatol. 2018. PMID: 30005097
The Effectiveness and Value of Siponimod for Secondary Progressive Multiple Sclerosis.
Synnott PG, Bloudek LM, Sharaf R, Carlson JJ, Pearson SD. Synnott PG, et al. Among authors: carlson jj. J Manag Care Spec Pharm. 2020 Mar;26(3):236-239. doi: 10.18553/jmcp.2020.26.3.236. J Manag Care Spec Pharm. 2020. PMID: 32105176
Author Reply.
Zimmermann M, Lubinga SJ, Banken R, Rind D, Cramer G, Synnott PG, Chapman RH, Khan S, Carlson J. Zimmermann M, et al. Among authors: carlson j. Value Health. 2019 Aug;22(8):972-973. doi: 10.1016/j.jval.2019.03.009. Epub 2019 Jul 22. Value Health. 2019. PMID: 31426939 Free article. No abstract available.
Cost-effectiveness of Drugs to Treat Relapsed/Refractory Multiple Myeloma in the United States.
Carlson JJ, Guzauskas GF, Chapman RH, Synnott PG, Liu S, Russo ET, Pearson SD, Brouwer ED, Ollendorf DA. Carlson JJ, et al. J Manag Care Spec Pharm. 2018 Jan;24(1):29-38. doi: 10.18553/jmcp.2018.24.1.29. J Manag Care Spec Pharm. 2018. PMID: 29290170
Cost-effectiveness analysis of low-dose direct oral anticoagulant (DOAC) for the prevention of cancer-associated thrombosis in the United States.
Li A, Carlson JJ, Kuderer NM, Schaefer JK, Li S, Garcia DA, Khorana AA, Carrier M, Lyman GH. Li A, et al. Among authors: carlson jj. Cancer. 2020 Apr 15;126(8):1736-1748. doi: 10.1002/cncr.32724. Epub 2020 Jan 30. Cancer. 2020. PMID: 31999844
THE AUTHORS RESPOND.
Roth JA, Carlson JJ, Xia F, Williamson T, Sullivan SD. Roth JA, et al. Among authors: carlson jj. J Manag Care Spec Pharm. 2020 Dec;26(12):1617-1618. doi: 10.18553/jmcp.2020.26.12.1617. J Manag Care Spec Pharm. 2020. PMID: 33251990
Disease-Modifying Therapies for Relapsing-Remitting and Primary Progressive Multiple Sclerosis: A Cost-Utility Analysis.
Zimmermann M, Brouwer E, Tice JA, Seidner M, Loos AM, Liu S, Chapman RH, Kumar V, Carlson JJ. Zimmermann M, et al. Among authors: carlson jj. CNS Drugs. 2018 Dec;32(12):1145-1157. doi: 10.1007/s40263-018-0566-9. CNS Drugs. 2018. PMID: 30141001
The Potential Long-Term Comparative Effectiveness of Larotrectinib and Entrectinib for Second-Line Treatment of TRK Fusion-Positive Metastatic Lung Cancer.
Roth JA, Carlson JJ, Xia F, Williamson T, Sullivan SD. Roth JA, et al. Among authors: carlson jj. J Manag Care Spec Pharm. 2020 Aug;26(8):981-986. doi: 10.18553/jmcp.2020.20045. Epub 2020 Apr 24. J Manag Care Spec Pharm. 2020. PMID: 32329651
Performance-Based Risk-Sharing Arrangements: An Updated International Review.
Carlson JJ, Chen S, Garrison LP Jr. Carlson JJ, et al. Pharmacoeconomics. 2017 Oct;35(10):1063-1072. doi: 10.1007/s40273-017-0535-z. Pharmacoeconomics. 2017. PMID: 28695544 Review.
Defining and Managing High-Priced Cures: Healthcare Payers' Opinions.
Yeung K, Suh K, Garrison LP Jr, Carlson JJ. Yeung K, et al. Among authors: carlson jj. Value Health. 2019 Jun;22(6):648-655. doi: 10.1016/j.jval.2018.11.012. Epub 2019 May 17. Value Health. 2019. PMID: 31198181 Free article.
81 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback